Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
BioXcel Therapeutics, Inc. - Common Stock
(NQ:
BTAI
)
2.310
-0.070 (-2.94%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioXcel Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Why BioXcel Therapeutics Stock Flopped Again Today
August 15, 2023
Major changes are afoot with the company, and few are happy about them.
Via
The Motley Fool
Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy
August 15, 2023
Mizuho analyst Graig Suvannavejh downgraded BioXcel Therapeutics, Inc. (NASDAQ: BTAI) to Neutral from Buy,
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
August 15, 2023
Via
Benzinga
Analyst Expectations for BioXcel Therapeutics's Future
August 15, 2023
Via
Benzinga
A Preview Of BioXcel Therapeutics's Earnings
August 11, 2023
Via
Benzinga
NVIDIA To Rally More Than 23%? Here Are 10 Other Analyst Forecasts For Tuesday
August 15, 2023
B of A Securities lowered the price target for Valero Energy Corporation (NYSE: BMBL) from $160 to $152. B of A Securities analyst Doug Leggate downgraded the stock from Buy to Neutral. Valero Energy...
Via
Benzinga
ROSEN, A LEADING LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
August 14, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations
August 14, 2023
From
Gibbs Law Group
Via
Business Wire
Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher
August 14, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 90 points on Monday. The Dow traded down 0.14% to 35,232.62 while the NASDAQ rose 0.66% to 13,735.42. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
August 14, 2023
Via
Benzinga
3 Biotech Stocks to Sell in August Before They Crash and Burn
August 14, 2023
These biotech stocks are set to crash and burn, so it's probably a good idea for investors to sell in August, before it's too late.
Via
InvestorPlace
US Stocks Turn Higher; BioXcel Therapeutics Shares Plummet
August 14, 2023
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 80 points on Monday. The Dow traded up 0.01% to 35,284.34 while the NASDAQ rose 0.64% to 13,732.05....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 14, 2023
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration...
Via
Benzinga
Why BioXcel Therapeutics Stock Is Getting Crushed Today
August 14, 2023
BioXcel just announced a big change.
Via
The Motley Fool
CLF Stock Alert: U.S. Steel Rejects Cleveland-Cliffs Bid
August 14, 2023
Cleveland-Cliffs (CLF) stock is worth checking on today after the company's takeover bill for United States Steel (X) was rejected.
Via
InvestorPlace
FFIE Stock Alert: Faraday Future Delivers Its First FF 91
August 14, 2023
Faraday Future (FFIE) stock is a hot topic on Monday after the EV company delivered its first FF 91 2.0 Futurist Alliance.
Via
InvestorPlace
PYPL Stock Alert: What to Know as PayPal Names New CEO
August 14, 2023
PayPal (PYPL) stock is in the news Monday as investors react to the finance transfer company naming Alex Chriss as its next CEO.
Via
InvestorPlace
Why Is BioXcel Therapeutics (BTAI) Stock Down 46% Today?
August 14, 2023
BioXcel Therapeutics (BTAI) stock is taking a beating on Monday after the biopharmaceutical company announced major layoffs.
Via
InvestorPlace
Dow Falls 50 Points; Monday.com Posts Upbeat Results
August 14, 2023
U.S. stocks traded mostly lower this morning, with the Dow Jones falling around 50 points on Monday. Following the market opening Monday, The Dow traded down 0.14% to 35,230.38 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
August 14, 2023
Via
Benzinga
BTAI DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.
August 14, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
August 13, 2023
WHY: New York, NY - (NewMediaWire) - August 13, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
August 13, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
August 12, 2023
WHY: New York, NY - (NewMediaWire) - August 12, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, A RESPECTED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
August 12, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GDS, Arrow, ImmunityBio, and BioXcel and Encourages Investors to Contact the Firm
August 11, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
NASDAQ: BTAI Investor Notice Lawsuit Alleges Securities Laws Violations by BioXcel Therapeutics, Inc.
August 11, 2023
San Diego, CA -- (SBWIRE) -- 08/11/2023 -- An investor, who purchased shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI), filed a lawsuit over alleged violations of Federal Securities Laws by BioXcel...
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, A LEADING NATIONAL FIRM, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BTAI
August 08, 2023
WHY: New York, NY - (NewMediaWire) - August 08, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December...
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.
August 08, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioXcel, Seagate, Baxter, and Danaher and Encourages Investors to Contact the Firm
August 06, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.